Project Details
Description
Phase I Study of ACTR707, an Autologous T cell Product, in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/17 → 8/30/21 |
Funding
- UNUM THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.